Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context

Advances in Therapy

Volumn 31, Issue 8, 2014, Pages 873-890

  Caresano, Chiara ^a   Di Sciascio, Guido ^b   Fagiolini, Andrea ^c   Maina, Giuseppe ^d   Perugi, Giulio ^e,f   Ripellino, Claudio ^g   Vampini, Claudio ^h  

^a H LUNDBECK A S   (Denmark)

^b POLICLINICO   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^g CSD Medical Research Srl   (Italy)

^h UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Asenapine; Bipolar disorder; Cost effectiveness analysis (CEA); Mixed episodes; Olanzapine; Psychiatry

Indexed keywords

ASENAPINE; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT; OLANZAPINE;

BIPOLAR DISORDER; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICE; HUMAN; ITALY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REPRODUCIBILITY; STATISTICAL MODEL; UTILIZATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; HEALTH SERVICES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ITALY; MODELS, ECONOMETRIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS;

EID: 84939892586     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0139-3     Document Type: Article

References (47)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C., USA, 2000.
2. Fagiolini A, Forgione R, Maccari M, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148(2–3):161–9.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet. 1997;349(9063):1436–42.
4. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227–33.
5. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012;15(7):1015–26.
6. Zajecka JM. Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder. CNS Spectr. 2005;11(Suppl 13):1–16.
7. Perugi G, Akiskal HS, Micheli C, et al. Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases. J Affect Disord. 1997;43(3):169–80.
8. Akiskal HS, Benazzi F. Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states? Psychopathology. 2005;38(5):273–80.
9. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated, “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85(3):245–58.
10. Zarate CA, Tohen MF. Bipolar disorder and comorbid substance use disorders, in Substance abuse in the mentally and physically disabled, Chap. 4. New York: Marcel Dekker Inc; 2005. p. 64.
11. Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013;170(1):31–42.
12. Filaković P, Petek Erić A, Požgain I. New strategies in the treatment of bipolar disorder. Psychiatria Danubina. 2011;23(3):293–9.
13. Grunze H, Azorin JM. Clinical decision making in the treatment of mixed states. World J Biol Psychiatry. 2014 (Epub ahead of print).
14. Muralidharan K, Ali M, Silveira LE, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials. J Affect Disord. 2013;150(2):408–14.
15. McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013;150(2):378–83.
16. Saphris: Highlights of prescribing information. Available from: https://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdf (Last accessed April 01, 2014).
17. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013;145(1):62–9.
18. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–86.
19. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1):27–38.
20. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815–26.
21. All Wales Medicines Strategy Group (AWMSG). Aripiprazole tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole. AWMSG Secretariat Assessment Report Advice, no. 1209, 2009.
22. Klok RM, Al Hadithy AF, van Schayk NP, et al. Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder. Expert Rev Pharmacoecon Outcomes Res. 2007;7(5):459–67.
23. McKendrick J, Cerri KH, Lloyd A, D’Ausilio A, Dando S, Chinn C. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol. 2007;21(6):588–96.
24. Ramirez de Arellano A, Rubio-Terres C, Baca E, et al. Economic evaluation analysis in the treatment of bipolar disorder with aripiprazole and other atypical antipsychotic drugs in Spain. Presented at ISPOR 13th Annual European Congress, Prague, 2010.
25. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry. 2005;187:559–67.
26. Fajutrao L, Paulsson B, Liu S, Locklear J. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther. 2009;31(1):1456–68.
27. Sawyer L, Azorin JM, Chang S, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. J Med Econ. 2014;17(7):508–19.
28. Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. BMC Psychiatry. 2014;14:16.
29. Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics. 2012;30(6):513–30.
30. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. 2007;11(39):iii-iv, ix-206.
31. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011;129(1–3):14–26.
32. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012;32(1):46–55.
33. Vieta E, Suppes T, Ekholm B, Udd M, Gustafsson U. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord. 2012;142(1–3):36–44.
34. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029–49.
35. ISTAT. (2013) ISTAT—Health for all. Available from: http://www.istat.it/it/archivio/14562 (Last accessed April 01, 2014).
36. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002;668(2–3):167–81.
37. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011–7.
38. Niufan G, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord. 2008;105(1–3):101–8.
39. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–18.
40. CODIFA. Informatore Farmaceutico (2014). Available from: http://www.codifa.it/ (Last accessed April 01, 2014).
41. Ministero della Salute. (2014) Ministero della Salute. Available from: http://www.salute.gov.it/ (Last accessed April 01, 2014).
42. NICE. National Institute for Health and Care Excellence (2013). Available from: http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9 (Last accessed April 01, 2014).
43. Brunelle J, Consoli A, Tanguy ML, et al. Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart review. Eur Child Adolesc Psychiatry. 2009;18(3):185–93.
44. Ouanes S, Chenoufi L, Cheour M. An update on the treatment of mixed bipolar states: what is new in 2013? J Affect Disord. 2014;158:53–5.
45. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014;75(3):238–45.
46. Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res. 2006;15(7):1271–80.
47. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.